Molecular diagnostic technologies for COVID-19 : Limitations and challenges
© 2020 The Author. Published by Elsevier B.V. on behalf of Cairo University..
BACKGROUND: To curb the spread of the COVID-19 (coronavirus disease 2019) pandemic, the world needs diagnostic systems capable of rapid detection and quantification of the novel coronavirus (SARS-CoV-2). Many biomedical companies are rising to the challenge and developing COVID-19 diagnostics. In the last few months, some of these diagnostics have become commercially available for healthcare workers and clinical laboratories. However, the diagnostic technologies have specific limitations and reported several false-positive and false-negative cases, especially during the early stages of infection.
AIM: This article aims to review recent developments in the field of COVID-19 diagnostics based on molecular technologies and analyze their clinical performance data.
KEY CONCEPTS: The literature survey and performance-based analysis of the commercial and pre-commercial molecular diagnostics address several questions and issues related to the limitations of current technologies and highlight future research and development challenges to enable timely, rapid, low-cost, and accurate diagnosis of emerging infectious diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Journal of advanced research - 26(2020) vom: 07. Nov., Seite 149-159 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Afzal, Adeel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 12.11.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jare.2020.08.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314111816 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314111816 | ||
| 003 | DE-627 | ||
| 005 | 20231225152031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jare.2020.08.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314111816 | ||
| 035 | |a (NLM)32837738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Afzal, Adeel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular diagnostic technologies for COVID-19 |b Limitations and challenges |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 The Author. Published by Elsevier B.V. on behalf of Cairo University. | ||
| 520 | |a BACKGROUND: To curb the spread of the COVID-19 (coronavirus disease 2019) pandemic, the world needs diagnostic systems capable of rapid detection and quantification of the novel coronavirus (SARS-CoV-2). Many biomedical companies are rising to the challenge and developing COVID-19 diagnostics. In the last few months, some of these diagnostics have become commercially available for healthcare workers and clinical laboratories. However, the diagnostic technologies have specific limitations and reported several false-positive and false-negative cases, especially during the early stages of infection | ||
| 520 | |a AIM: This article aims to review recent developments in the field of COVID-19 diagnostics based on molecular technologies and analyze their clinical performance data | ||
| 520 | |a KEY CONCEPTS: The literature survey and performance-based analysis of the commercial and pre-commercial molecular diagnostics address several questions and issues related to the limitations of current technologies and highlight future research and development challenges to enable timely, rapid, low-cost, and accurate diagnosis of emerging infectious diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical sensitivity | |
| 650 | 4 | |a In vitro diagnostics | |
| 650 | 4 | |a Point-of-care | |
| 650 | 4 | |a Real-time RT-PCR | |
| 650 | 4 | |a SARS-CoV-2 | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of advanced research |d 2013 |g 26(2020) vom: 07. Nov., Seite 149-159 |w (DE-627)NLM246273542 |x 2090-1224 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2020 |g day:07 |g month:11 |g pages:149-159 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jare.2020.08.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2020 |b 07 |c 11 |h 149-159 | ||